• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Around $8.5M Bet On Eagle Bulk Shipping? Check Out These 4 Stocks Insiders Are Buying

    6/23/23 8:46:34 AM ET
    $ASAN
    $EGLE
    $HHC
    $VERA
    Computer Software: Prepackaged Software
    Technology
    Marine Transportation
    Consumer Discretionary
    Get the next $ASAN alert in real time by email

    Although US stocks closed mostly higher on Thursday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    Eagle Bulk Shipping

    • The Trade: Eagle Bulk Shipping Inc. (NYSE:EGLE) 10% owner Danaos Corp acquired a total of 181,422 shares an average price of $47.28. To acquire these shares, it cost around $8.58 million.
    • What’s Happening: Eagle Bulk Shipping purchased Oaktree Capital stake in company for $58 per share.
    • What Eagle Bulk Shipping Does: Eagle Bulk Shipping Inc is a U.S.-based, fully integrated shipowner-operator, providing global transportation solutions to miners, producers, traders and end users.

    Howard Hughes

    • The Trade: The Howard Hughes Corporation (NYSE:HHC) Director William Ackman acquired a total of 62,498 shares at an average price of $74.80. To acquire these shares, it cost around $4.67 million.
    • What’s Happening: Howard Hughes posted a narrower-than-expected quarterly loss.
    • What Howard Hughes Does: The Howard Hughes Corp is a real estate company that develops master-planned communities (MPCs) and is involved in other strategic real estate development opportunities across the United States.

    Don’t forget to check out our premarket coverage here

    Asana

    • The Trade: Asana, Inc. (NYSE:ASAN) Director, President, CEO, & Chair Dustin Moskovitz bought a total of 240,000 shares at an average price of 23.16. To acquire these shares, it cost around $5.56 million. The company’s Director, however, sold 9,933 shares.
    • What’s Happening: Asana reported better-than-expected first-quarter financial results and issued FY24 EPS guidance above estimates.
    • What Asana Does: Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives.

    Check This Out: Investor Sentiment Improves After Nasdaq Snaps 3-Session Losing Streak

    Vera Therapeutics

    • The Trade: Vera Therapeutics, Inc. (NASDAQ:VERA) 10% owner Commodore Capital LP bought a total 448,217 shares at an average price of $15.17. The insider spent around $6.8 million to buy those shares.
    • What’s Happening: Vera Therapeutics said atacicept for IgA nephropathy met its primary and key secondary endpoints.
    • What Vera Therapeutics Does: Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases.
    Get the next $ASAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASAN
    $EGLE
    $HHC
    $VERA

    CompanyDatePrice TargetRatingAnalyst
    Asana Inc.
    $ASAN
    1/15/2026$16.00Neutral → Buy
    Citigroup
    Asana Inc.
    $ASAN
    12/17/2025Neutral
    BTIG Research
    Asana Inc.
    $ASAN
    12/15/2025$18.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Vera Therapeutics Inc.
    $VERA
    10/16/2025$48.00Buy
    BofA Securities
    Vera Therapeutics Inc.
    $VERA
    8/4/2025Outperform → Peer Perform
    Wolfe Research
    Asana Inc.
    $ASAN
    6/4/2025$13.00 → $10.00Hold → Reduce
    HSBC Securities
    Asana Inc.
    $ASAN
    5/20/2025$14.00Equal-Weight → Underweight
    Morgan Stanley
    Vera Therapeutics Inc.
    $VERA
    5/5/2025$75.00Buy
    H.C. Wainwright
    More analyst ratings

    $ASAN
    $EGLE
    $HHC
    $VERA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Enright Patrick G bought $249,985 worth of shares (5,882 units at $42.50) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    12/15/25 8:07:34 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Moskovitz Dustin A. bought $1,655,954 worth of shares (122,470 units at $13.52), increasing direct ownership by 0.21% to 57,898,436 units (SEC Form 4)

    4 - Asana, Inc. (0001477720) (Issuer)

    8/25/25 6:47:51 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Director Moskovitz Dustin A. bought $6,139,844 worth of shares (446,966 units at $13.74), increasing direct ownership by 0.78% to 57,775,966 units (SEC Form 4)

    4 - Asana, Inc. (0001477720) (Issuer)

    8/21/25 8:10:49 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    $ASAN
    $EGLE
    $HHC
    $VERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Asana upgraded by Citigroup with a new price target

    Citigroup upgraded Asana from Neutral to Buy and set a new price target of $16.00

    1/15/26 8:27:19 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    BTIG Research initiated coverage on Asana

    BTIG Research initiated coverage of Asana with a rating of Neutral

    12/17/25 9:13:10 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Asana upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Asana from Sector Weight to Overweight and set a new price target of $18.00

    12/15/25 8:56:16 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    $ASAN
    $EGLE
    $HHC
    $VERA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Asana to Present at Upcoming Investor Events

    Asana, Inc. (NYSE:ASAN)(LTSE: ASAN), a leading work management platform for human and AI collaboration, today announced that Asana's executives will present at the following investor events: KBCM Emerging Technology Summit on March 3, 2026 at 9:00 a.m. PT / 12:00 p.m. ET The Citizens Technology Conference on March 3, 2026 at 1:00 p.m. PT / 4:00 p.m. ET Morgan Stanley Technology, Media & Telecom Conference on March 4, 2026 at 10:45 a.m. PT / 1:45 p.m. ET A live webcast will be available on Asana's website at https://investors.asana.com. About Asana Asana is a leading work management platform for human and AI collaboration. Over 170,000 customers like Accenture, Amazon, Anthro

    2/27/26 4:05:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

    Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of MedicineU.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026Strong balance sheet bolstered by equity and debt financings in 2025 expected to be sufficient to fund company beyond atacicept approval and U.S. commercial launch BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a l

    2/26/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics to Participate at Upcoming Investor Conferences

    BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: TD Cowen 46th Annual Health Care ConferenceFormat: Fireside chat and 1x1 investor meetings Webcast: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/Etdv38YcyjD9fFRQNSrAUoDate: Tuesday, March 3, 2026Time: 11:10am ET Location: Boston, MA Barclays 28th Annual Global He

    2/24/26 8:00:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASAN
    $EGLE
    $HHC
    $VERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Brenner Robert sold $90,307 worth of shares (2,151 units at $41.98), decreasing direct ownership by 4% to 50,947 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/25/26 8:01:07 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, FINANCE, CHIEF ACCT OFFCR Young Joseph R sold $130,864 worth of shares (3,117 units at $41.98), decreasing direct ownership by 5% to 64,722 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/25/26 8:00:18 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Grant Sean sold $207,778 worth of shares (4,949 units at $41.98), decreasing direct ownership by 4% to 114,181 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/25/26 7:59:26 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASAN
    $EGLE
    $HHC
    $VERA
    SEC Filings

    View All

    SEC Form 10-K filed by Vera Therapeutics Inc.

    10-K - Vera Therapeutics, Inc. (0001831828) (Filer)

    2/26/26 5:25:11 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

    2/26/26 7:30:26 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Vera Therapeutics Inc.

    144 - Vera Therapeutics, Inc. (0001831828) (Subject)

    2/23/26 4:42:49 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASAN
    $EGLE
    $HHC
    $VERA
    Leadership Updates

    Live Leadership Updates

    View All

    Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

    BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. "We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "With his track record

    1/28/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

    BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics' Board of Directors. "We are thrilled to welcome Jim to our Board of Directors at this pivotal point in Vera Therapeutics' history as we prepare to launch a potential first-in-class dual BAFF/APRIL inhibitor to transform the treatment of IgA nephropathy and other aut

    11/26/25 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Asana Appoints Arnab Bose as Chief Product Officer

    Former Okta Executive to Lead Product Strategy in New Era of Human + AI Collaboration Asana, Inc. (NYSE:ASAN) (LTSE: ASAN), a leading enterprise work management platform for human + AI collaboration, today announced that Arnab Bose will join the company as Chief Product Officer, effective September 16, 2025. Bose will lead Asana's product strategy and innovation, as the company focuses on helping customers realize the productivity gains promised by AI and human teamwork. Bose joins Asana from Okta, where he served as Chief Product Officer, driving vision and strategy for both Workforce Identity and Customer Identity solutions—essentially building the orchestration layer that connects mi

    9/9/25 12:00:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    $ASAN
    $EGLE
    $HHC
    $VERA
    Financials

    Live finance-specific insights

    View All

    Asana Announces Third Quarter Fiscal 2026 Results

    Q3 revenue exceeded high-end of guidance Raises both high-end of FY26 revenue and non-GAAP operating income guidance ranges Announced AI Teammates: collaborative agents that understand the context of all work across the organization and deliver real business outcomes Asana, Inc. (NYSE:ASAN)(LTSE: ASAN), a leading work management platform for human and AI collaboration, today reported financial results for its third quarter fiscal 2026 ended October 31, 2025. "This was a solid quarter, with continued improvement in NRR and momentum with AI Studio," said Dan Rogers, Chief Executive Officer of Asana. "Our newly announced AI Teammates bring collaborative, context-aware agents with the right c

    12/2/25 4:05:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Asana Announces Second Quarter Fiscal 2026 Results

    Q2 revenue exceeded high end of guidance; raises midpoint of FY26 revenue guidance range Q2 GAAP operating margin improved 18 percentage points year over year; Q2 non-GAAP operating margin improved 16 percentage points year over year Raises FY26 non-GAAP operating margin guidance Asana, Inc. (NYSE:ASAN)(LTSE: ASAN), a leading work management platform for human and AI collaboration, today reported financial results for its second quarter fiscal 2026 ended July 31, 2025. "Every company is looking for the productivity unlock from AI. With the Asana Work Graph and AI Studio, we bring AI workflows directly into the flow of work—so teams move faster, operate more efficiently, and deliver

    9/3/25 4:05:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Asana Announces First Quarter Fiscal 2026 Results

    Q1 revenue exceeded high end of guidance Q1 GAAP operating margin improved 15 percentage points year over year; Achieved first positive non-GAAP operating margin in company history AI Studio exceeded $1M ARR in its first quarter of general availability Asana, Inc. (NYSE:ASAN)(LTSE: ASAN), a leading work management platform for human + AI coordination, today reported financial results for its first quarter fiscal 2026 ended April 30, 2025. "Just months after launching AI Studio, we've already crossed $1 million in ARR and head into Q2 with a robust, rapidly growing global pipeline," said Dustin Moskovitz, Co‑Founder and CEO of Asana. "With new offerings like the AI Studio Plus package, a

    6/3/25 4:05:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    $ASAN
    $EGLE
    $HHC
    $VERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

    SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 4:10:28 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

    SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 4:05:17 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Vera Therapeutics Inc.

    SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 1:22:39 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care